BioSante Pharmaceuticals to Present at the Oppenheimer Health Care Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO, will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as give a LibiGel(R) (testosterone gel) update at the Oppenheimer 20th Annual Healthcare Conference to be held on November 3-4, 2009 at the Waldorf-Astoria in New York City. Mr. Simes will present on November 3, 2009 at 1:00 pm local time.

A live audio webcast of BioSante's presentation at the conference may be accessed at Oppenheimer Health Care Conference. A replay of the presentation will be available at the same link.

About the Oppenheimer Health Care Conference

This Oppenheimer Annual Healthcare Conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders. The companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook(TM)), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, which BioSante acquired from Cell Genesys, Inc. and are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Additional information is available online at: www.biosantepharma.com.

SOURCE: BioSante Pharmaceuticals, Inc.

Alan Zachary, 
McKinney/Chicago 
(312) 944-6784 ext. 316 
azachary@mckinneychicago.com 
For information about participating in the LibiGel clinical studies call or visit the following: 
877-BLOOM81; www.bloomstudy.com

Related terms: acquisition, biotechnology, cancer, ceo, clinical, conference, contraception, environment, fda, health, healthcare, local, market, medical, medicine, menopause, nasdaq, new york, online, patent, pharmaceuticals, policy, president, products, swine, technology, vaccine